Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
April 18, 2024 06:30 ET
|
Cerevel Therapeutics
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with...
Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
November 29, 2023 06:30 ET
|
Cerevel Therapeutics
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET ...
Cerevel Therapeutics to Present at Upcoming Investor Conferences
November 08, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 01, 2023 06:30 ET
|
Cerevel Therapeutics
Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on...
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
October 13, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
October 11, 2023 22:45 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases,...
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
October 11, 2023 16:01 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases,...
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
August 02, 2023 06:30 ET
|
Cerevel Therapeutics
Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated ...
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
July 05, 2023 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...